April 29, 2025

Flu Shots Linked to Temporary Menstrual Changes

Study shows small, temporary cycle length increases after vaccination

Conexiant

April 28, 2025

Most Long COVID Cases Persist Beyond 2 Years

In a three-year follow-up study, fewer than 2% of long COVID cases reported resolution of symptoms, with vaccinated patients demonstrating significantly better physical and mental health outcomes.

Conexiant

April 25, 2025

FDA Approves Penpulimab-kcqx for NPC

The FDA approved penpulimab-kcqx for first line and previously treated recurrent or metastatic non-keratinizing nasopharyngeal carcinoma.

Conexiant

April 23, 2025

Sense of Belonging 'Critical' for Workplace Retention

Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.

Conexiant

April 23, 2025

More Data, Please: FDA to Novavax

Novavax reveals FDA's request for more clinical data if COVID-19 vaccine is approved and expresses confidence in approval based on discussions.

Reuters

April 18, 2025

Vaccination May Lower RA Risk

Researchers found no increased risk of rheumatoid arthritis following vaccination. In fact, they observed short-term protective effects against RA.

Conexiant

April 16, 2025

RSV Vaccine Access Under CDC Review

“An estimated 15,000–20,000 annual RSV-associated hospitalizations occur in adults aged 50–59”—prompting CDC advisers to revisit age-based vaccine recommendations.

Reuters

April 16, 2025

CONSORT 2025: Setting New Standards for Clinical Trial Reporting

"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.

Conexiant

April 15, 2025

Coadministration of RSV and COVID-19 Vaccines Safe, Study

Coadministration of mRNA-1345 with a standard-dose quadrivalent inactivated influenza vaccine or bivalent mRNA-1273.214 COVID-19 vaccine was generally safe and elicited mostly noninferior immune responses in adults aged 50 years and older.

Conexiant